Fate Therapeutics, Inc. (FATE)
1.33
-0.05
(-3.62%)
USD |
NASDAQ |
Mar 06, 16:00
1.36
+0.03
(+2.26%)
Pre-Market: 20:00
Fate Therapeutics Research and Development Expense (TTM) : 94.93M for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| MannKind Corp. | 66.35M |
| Vertex Pharmaceuticals, Inc. | 3.929B |
| Ardelyx, Inc. | 68.47M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |